Toronto, ON, December 19, 2013 – Imagistx has closed a $4.2M round of financing led by iGan Partners, IAF, Veddis Ventures and angel investors. The company is also negotiating further commitments from major strategic investors. The financing will be used by Imagistx to conduct large scale multi-site clinical trials, further enhance its leading prostate ultrasound imaging system and bring its products to market worldwide.
Imagistx has developed the world’s only ultra high frequency ultrasound technology that will dramatically improve prostate cancer detection rates over the current standard of care. The increased resolution and frequency allows for early detection and diagnosis of prostate cancer. It will also provide valuable monitoring tools, supporting a growing trend towards active surveillance. The clinical trials will take place at five leading urology centres across North America lead by John Hopkins.
“We are thankful for the confidence our shareholders have shown in the Imagistx team with their recent investment. This capital will allow us to clinically validate the superiority of our product, and carry out our corporate strategy.“ said Randy AuCoin, President of Imagistx.
“We are excited about the investment in Imagistx and have confidence in the superiority of their product. Randy and his team have enormous potential to lead the company and revolutionize the way prostate cancer is detected and treated“ said Sam Ifergan, President of iGan Partners.
About Imagistx Inc
Imagistx has developed an ultra high resolution system that provides significant improvements in detecting prostate cancer. Its ultrasound system allows urologists to see exquisite details of the prostate, allowing for better diagnosis, surveillance and treatment. For more information, please visit www.imagistxprostate.com.